Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15 by Hope, VD et al.
Hope, VD and McVeigh, J and Smith, J and Glass, R and Njoroge, J and
Tanner, C and Parry, JV and Ncube, F and Desai, M (2017)Low levels of
hepatitis C diagnosis and testing uptake among people who inject image and
performance enhancing drugs in England and Wales, 2012-15. Drug and
Alcohol Dependence, 179. pp. 83-86. ISSN 0376-8716
Downloaded from: http://e-space.mmu.ac.uk/624830/
Version: Accepted Version
Publisher: Elsevier
DOI: https://doi.org/10.1016/j.drugalcdep.2017.06.018
Please cite the published version
https://e-space.mmu.ac.uk
Accepted Manuscript
Title: Low levels of hepatitis C diagnosis and testing uptake
among people who inject image and performance enhancing
drugs in England and Wales, 2012-15
Authors: V.D. Hope, J. McVeigh, J. Smith, R. Glass, J.
Njoroge, C. Tanner, J.V. Parry, F. Ncube, M. Desai
PII: S0376-8716(17)30342-3
DOI: http://dx.doi.org/doi:10.1016/j.drugalcdep.2017.06.018
Reference: DAD 6550
To appear in: Drug and Alcohol Dependence
Received date: 21-4-2017
Revised date: 12-6-2017
Accepted date: 13-6-2017
Please cite this article as: Hope, V.D., McVeigh, J., Smith, J., Glass, R., Njoroge,
J., Tanner, C., Parry, J.V., Ncube, F., Desai, M., Low levels of hepatitis C
diagnosis and testing uptake among people who inject image and performance
enhancing drugs in England and Wales, 2012-15.Drug and Alcohol Dependence
http://dx.doi.org/10.1016/j.drugalcdep.2017.06.018
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
Low levels of hepatitis C diagnosis and testing uptake among people who inject image and 
performance enhancing drugs in England and Wales, 2012-15 
 
 
 
 
Hope, V.D.1,2; McVeigh, J.1; Smith, J.3; Glass, R.2; Njoroge, J.2;  
Tanner, C.2; Parry, J.V.2; Ncube, F.2; Desai, M.2 
 
 
 
 
1. Public Health Institute, LJMU, Liverpool, UK  
2. National Infections Service, Public Health England, London, UK 
3. Public Health Wales, Cardiff, UK 
 
 
 
 
 
Correspondence: 
Vivian D. Hope 
Liverpool John Moores University 
Public Health Institute  
70 Mount Pleasant, Liverpool L3 5UA, UK 
Email: vivian.hope@phe.gov.uk 
 
Highlights 
 One in 20 people who inject image & performance enhancing drugs (IPEDs) have hepatitis 
C antibodies 
 Uptake of hepatitis C testing was poor; less than two-fifths had ever been tested  
 Among those only injecting IPEDs, most were not aware of having hepatitis C antibodies 
 
Abstract 
Introduction: People injecting image and performance enhancing drugs (IPEDs) have 
traditionally not been perceived as being at high risk of hepatitis C virus (HCV) infection. 
However, recent studies indicate the HCV antibody (anti-HCV) prevalence in this group is 
10-times that in the general population. HCV testing uptake and undiagnosed infections are 
examined using data from a voluntary unlinked-anonymous survey. 
Method: People injecting IPEDs across England and Wales completed a short bio-
behavioural survey (2012-15). Anti-HCV status and self-reports of HCV testing were used in 
the analysis. 
Results: The participants median age was 31 years, 98% were men, 14% had also injected 
psychoactive drugs and the anti-HCV prevalence was 4.8% (N=564). Among those who had 
never injected psychoactive drugs the anti-HCV prevalence was 1.4%; among those who had 
recently injected psychoactive drugs (preceding 12 months) prevalence was 39% and among 
those who had done this previously 14% (p<0.001). Overall, 37% had been tested for HCV: 
among those who had recently injected psychoactive drugs 78% had been tested, as had 56% 
of those who had injected psychoactive drugs previously; 33% of those never injecting 
psychoactive drugs were tested (p<0.001). Overall, 44% of those with anti-HCV were aware 
of this; however, only 14% of those who had never injected psychoactive drugs were aware. 
Conclusions: One-in-twenty people who inject IPEDs have anti-HCV. HCV infections 
among those who had never injected psychoactive drugs were mostly undiagnosed, though 
this group had a lower prevalence. Targeted HCV testing interventions are also needed for 
those injecting IPEDs. 
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1.0 Introduction 
The injection and use of image and performance enhancing drugs (IPEDs) has, over recent 
decades, grown substantially in many countries, including the United Kingdom (UK) (ACMD, 2010; 
Iversen et al., 2013). IPEDs are a range of enhancement substances that are used to increase 
muscularity, strength, or to modify appearance (Evans-Brown et al., 2012). IPEDs can be taken either 
orally, or via intramuscular and subcutaneous injections, with the most commonly injected IPEDs in 
the UK being drugs marketed as anabolic steroids, growth hormone, human chorionic gonadotrophin, 
and melanotan (Bates and McVeigh, 2016). However, the range of IPEDs being used and injected is 
expanding, and psychoactive drugs can be used concurrently, therefore increasing harm (Sagoe et al., 
2015). 
Historically, people who inject IPEDs, unlike other groups of people who inject drugs 
(PWID), have not been perceived as being at high risk of hepatitis C and other blood borne viral 
infections, such as HIV (Crampin et al., 1998; Day et al., 2008). However, recent UK studies indicate 
that the prevalence of antibodies to hepatitis C virus (anti-HCV) in this group is 10 times that found in 
the general population, though it remains much lower than that found among those who inject 
psychoactive drugs (Hope et al., 2013). The advent of the new highly efficacious (>90%), well-
tolerated direct acting antiviral (DAA) drugs for treating hepatitis C means this infection can now be 
easily cured (EASL, 2014). However, access to these DAA treatments requires the hepatitis C 
infection to be diagnosed.  
In this paper, we present the first examination of the extent of undiagnosed hepatitis C 
infections among people who inject IPEDs. The uptake of diagnostic testing for hepatitis C and the 
extent of undiagnosed infection in this population are examined using data from a bio-behavioural 
survey of people injecting IPEDs in England and Wales. 
2.0 Methods 
Data from a national cross-sectional unlinked-anonymous survey were used. A biennial 
survey of people injecting IPEDs is undertaken as part of the UKs bio-behavioural surveillance of 
PWID. Methodological details have been published previously (Cullen et al., 2015b; Hope et al., 
2013; Noone et al., 1993). Participants recruited from across England and Wales complete a short 
behavioural questionnaire and provide a dried-blood spot (DBS) sample. Participation is voluntary 
and recruitment occurs through sentinel sites that provide services, such as, needle and syringe 
programmes (NSPs) and outreach, to people injecting IPEDs. The DBS samples collected are tested 
for anti-HCV using published methods (Cullen et al., 2015b). The surveillance programme has ethical 
approval. 
Data from two survey waves (2012-2013 and 2014-2015) were used in this analysis. 
Participants in the second wave who reported participation in the first wave were excluded from the 
analyses. Hepatitis C testing uptake and the extent of ‘undiagnosed’ hepatitis C infections, were 
explored using participants’ current anti-HCV status from the testing of their DBS samples, and their 
self-reported uptake of hepatitis C testing and of their most recent test result. All analyses were 
undertaken using SPSS. 
3.0 Results 
During 2012-2015, 564 individuals who had ever injected IPEDs participated in the study: 
their median age at time of participation was 31 years (mean 32 years), the majority (98%, n=537) 
were men, 25% (n=137) had been imprisoned and 95% (n=531) had been born in the UK. During the 
year preceding participation, 95% (n=533) reported that they had injected drugs they believed to 
anabolic steroids, 41% (n=231) growth hormone, 34% (n=192) human chorionic gonadotropin, and 
17% (n=95) melanotan. One in seven participants (14%, n=79) had also injected a psychoactive drug 
(including heroin [7.6%, n=43], cocaine [6.9%, n=39], and amphetamine [6.7%, n=38]) at some point; 
with 6.4% (n=36) having injected a psychoactive drug during the year preceding their participation. 
Among those who had injected a psychoactive drug during the preceding year, the most commonly 
reported psychoactive drug that they had ever injected was amphetamine (75%, n=27/36). 
The overall prevalence of anti-HCV was 4.8% (27/564); those with anti-HCV were older 
(median age for those antibody positive 39 years vs. 30 years for those negative, p<0.001) and they 
were more likely to have ever been in prison (63% of those anti-HCV positive had ever been 
imprisoned vs. 24% of those anti-HCV negative, p<0.001). Prevalence of anti-HCV was higher 
(p<0.001) among those participants who had ever injected psychoactive drugs (25%) compared with 
those who had only injected IPEDs (1.4%), see Table 1.  
Overall, 37% (211/564) reported that they had ever had a diagnostic test for hepatitis C, those 
tested for hepatitis C were older (median age 33 years vs. 29 years for those never tested, p<0.001) 
and more likely to have ever been in prison (36% of those tested had been imprisoned vs 19% of those 
never tested, p<0.001). Uptake of diagnostic hepatitis C testing was highest among those participants 
who had recently injected psychoactive drugs (78%, p<0.001), see Table 1. Overall, 13% (71/564) of 
the participants reported that they had ever shared a needle, syringe or drugs vial. Sharing was more 
commonly reported among those who had ever injected psychoactive drugs (32%, 25/79 vs. 9.5%, 
46/485, p<0.001). However, sharing of injecting equipment was not associated with ever having been 
tested for hepatitis C (15%, 32/211 of those tested shared vs. 11%, 39/353 of those never tested, 
p=0.154). Additionally, sharing was not associated with testing among those participants who had 
also ever injected a psychoactive drug (36%, 19/52 of those tested vs. 22%, 6/27 of those not, p=0.194) 
and among those who had never injected a psychoactive drug (8.2% 13/159 of those tested vs. 10%, 
33/326 of those not, p=0.492). 
Those who reported that they had ever been tested for hepatitis C were asked to provide the 
year of their last test, only 134 (64%) reported this. Of these, 54% (73) reported their last hepatitis C 
test as being recent (i.e., either in the year they were recruited or in the preceding calendar year); the 
ages of those recently tested and those not recently tested were similar (35 years and 33 years 
respectively, p=0.176). The proportion recently tested for hepatitis C was similar among those who 
had also injected psychoactive drugs (62%, 21/34) and those who had never injected a psychoactive 
drug (52%, 52/100; p=0.323).  
Of the participants with anti-HCV, 44% (12/27) reported that they were aware of their status; 
awareness was higher among those participants who had also injected psychoactive drug (55% 
vs.14% for those who had not also injected psychoactive drug, p=0.091), see Table 1. Of those who 
were unaware that they had ever had hepatitis C, two-fifths (40%, 6/15) had never injected a 
psychoactive drug. 
4.0 Discussion 
One in 20 of the people injecting IPEDs sampled had anti-HCV, a level comparable to 
previous findings (Ip et al., 2016). After excluding those who were also injecting psychoactive drugs, 
one in 70 of those injecting only IPEDs had antibodies. The uptake of hepatitis C testing was poor 
with less than two-fifths having ever been tested, and only half of those tested having been tested 
recently. Worryingly, among those who had only injected IPEDs most of those who had been infected 
with hepatitis C were not aware of this, and so could not access appropriate care and treatment with 
the new DAA drugs and may unknowingly put others at risk.  
The minority who had injected both IPEDs and psychoactive drugs had not only a higher 
hepatitis C prevalence but also higher uptake of testing than those who had just used IPEDs. However, 
among those injecting both IPEDs and psychoactive drugs the pattern of psychoactive drug use was 
different from that found among those who only inject psychoactive drugs in the UK (Public Health 
England, 2015), with much higher of levels cocaine and amphetamine injection. The higher levels 
amphetamine consumption might possibly be related to their IPEDs use (George, 2000; Momaya et al., 
2015), but this needs further examination. 
The hepatitis C prevalence found among those injecting IPEDs is higher than in the general 
UK population, approximately 0.7% (ECDC., 2010); however, it is lower than the 50% found among 
those PWID who use only psychoactive drugs (Public Health England, 2015). This difference in 
prevalence between those injecting psychoactive drugs and those injecting IPEDs probably reflects 
the IPED injecting population being younger, with fewer years injecting, and likely to inject less 
frequently (Hope et al., 2015; Iversen et al., 2016). Thus, at a population level, those who inject 
IPEDs will have had overall fewer life-time injections and so potential risk events. This difference 
may also reflect the risk of hepatitis C transmission when injecting subcutaneously or intramuscularly 
possibly being lower than when injecting intravenously (Paez Jimenez et al., 2009).  
The uptake of diagnostic testing for hepatitis C was low, with less than two-fifths ever tested 
overall, and only a third of those who had never injected a psychoactive drug were tested. This is 
much lower than the uptake among those who inject psychoactive drugs in the UK, four-fifths of 
whom report ever being tested for hepatitis C (Public Health England, 2015). The reasons for this 
lower level of uptake needs further investigation, but it may relate to those who use IPEDs and 
healthcare workers not perceiving a risk when injecting only IPEDs. This poor uptake among those 
injecting IPEDs is reflected in the high proportion of undiagnosed hepatitis C infections among this 
group The vast majority (over 85%) of the infections among those who injected IPEDs, but who had 
never injected a psychoactive drug, were unrecognised. These individuals will thus not be able to 
access the DAA treatments and so remain able to transmit hepatitis C to others. This level of 
unrecognised infection is higher than found among those using IPEDs who had also injected 
psychoactive drugs. It is also much higher than among those only injecting psychoactive drugs, 
around half of whom remain unaware of their hepatitis C status in the UK (Public Health England, 
2015). 
The low level of hepatitis C testing uptake, and the high proportion of infections that are 
undiagnosed, is a concern. It is possible that among those injecting IPEDs and not in contact with 
NSP and outreach services like those used to recruit our sample – a group that may be larger than the 
group in contact with services (Cullen et al., 2015a) – testing and awareness could possibly be even 
lower. Our findings indicate a clear need for interventions to improve testing uptake among those who 
inject IPEDs. Further research is needed to explore levels of awareness of hepatitis C risk; to identify 
the barriers to blood-borne virus testing among people who inject IPEDs; and to identify and develop 
the most effective approaches for delivering testing. However, improvements to the existing provision 
of testing services for PWID could be the most cost-effective approach as this would use existing 
infrastructure. This could be, for example, through offering testing for hepatitis C using DBS samples 
(Coats and Dillon, 2015) when delivering existing outreach NSP provision to people injecting IPEDs. 
People who inject IPEDs also use a range of general health services, including primary care, (Hope et 
al., 2013) so increased awareness of IPED use and the appropriate offer of testing in these settings 
could also be effective. 
There are a number of limitations to our study. Firstly, the DBS samples collected in the 
survey were only tested for anti-HCV, and not tested for hepatitis C RNA. Therefore, we cannot look 
at awareness of current hepatitis C infection. Secondly, data on the uptake of testing for hepatitis C 
and the result of the last test were from self-reports which may be subject to recall bias, though studies 
of PWID indicate that self-reports are reliable (De Irala et al., 1996; Latkin et al., 1993). Finally, due 
to limited data on the size and nature of this population, we are currently unable to assess 
representativeness of those recruited (ACMD, 2010). Considering these issues, our findings need to 
be generalised with caution. 
5.0 Conclusion  
Hepatitis C infection is common among people who inject IPEDs, though the prevalence is 
currently lower than among those who inject psychoactive drugs. Among those who had only ever 
injected IPEDs, the majority of those with hepatitis C were undiagnosed. There are also unrecognised 
hepatitis C cases among those who had injected both IPEDs and psychoactive drugs. Targeted 
interventions to improve the uptake of hepatitis C testing among people who inject IPEDs need to be 
developed, evaluated and implemented. 
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Table 1: Hepatitis C prevalence, uptake of diagnostic testing and awareness of status among people 
injecting image and performance enhancing drugs by psychoactive drug injection status, England and 
Wales, 2012-2015. 
 
  Total 
 Ever had a 
diagnostic test 
for hepatitis C  
Tested 
hepatitis C 
antibody positive 
 
Aware of 
hepatitis C 
positive status 
Never injected a 
psychoactive drug 485 
 
159 33%  7 1.4% 
 
1 14% 
Ever injected a 
psychoactive drug 79 
 
52 66%  20 25% 
 
11 55% 
Last injected a 
psychoactive drug over 
a year ago 
43 
 
24 56% 6 14%
 
4 67% 
Last injected a 
psychoactive drug 
during preceding year 
36 
 
28 78%  14 39%
 
7 50% 
Total 564 
 
211 37%  27 4.8% 
 
12 44% 
 
